Park Avenue Securities LLC grew its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 21.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,293 shares of the biopharmaceutical company’s stock after buying an additional 1,103 shares during the period. Park Avenue Securities LLC’s holdings in Intra-Cellular Therapies were worth $526,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also made changes to their positions in the company. Perceptive Advisors LLC lifted its holdings in shares of Intra-Cellular Therapies by 62.6% in the 2nd quarter. Perceptive Advisors LLC now owns 1,716,407 shares of the biopharmaceutical company’s stock valued at $117,557,000 after acquiring an additional 661,052 shares during the last quarter. Millennium Management LLC raised its position in Intra-Cellular Therapies by 214.5% during the second quarter. Millennium Management LLC now owns 889,102 shares of the biopharmaceutical company’s stock valued at $60,895,000 after purchasing an additional 606,358 shares during the period. Marshall Wace LLP bought a new stake in shares of Intra-Cellular Therapies in the 2nd quarter valued at approximately $34,178,000. Point72 Asset Management L.P. boosted its holdings in shares of Intra-Cellular Therapies by 218.9% in the 2nd quarter. Point72 Asset Management L.P. now owns 554,186 shares of the biopharmaceutical company’s stock worth $37,956,000 after purchasing an additional 380,420 shares during the period. Finally, Eagle Asset Management Inc. increased its position in shares of Intra-Cellular Therapies by 130.5% during the 3rd quarter. Eagle Asset Management Inc. now owns 624,759 shares of the biopharmaceutical company’s stock valued at $45,714,000 after purchasing an additional 353,723 shares during the last quarter. 92.33% of the stock is owned by hedge funds and other institutional investors.
Intra-Cellular Therapies Stock Down 0.1 %
Shares of NASDAQ ITCI opened at $127.07 on Friday. Intra-Cellular Therapies, Inc. has a twelve month low of $62.78 and a twelve month high of $128.00. The firm has a market cap of $13.47 billion, a PE ratio of -146.06 and a beta of 0.70. The business has a fifty day simple moving average of $91.53 and a two-hundred day simple moving average of $82.02.
Insider Transactions at Intra-Cellular Therapies
In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total value of $4,375,800.00. Following the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $91,834,228.20. The trade was a 4.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President Michael Halstead sold 22,869 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total transaction of $2,038,085.28. The disclosure for this sale can be found here. Corporate insiders own 2.60% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on the company. Needham & Company LLC restated a “hold” rating and issued a $100.00 price target on shares of Intra-Cellular Therapies in a research report on Monday, January 13th. Morgan Stanley raised their target price on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Royal Bank of Canada reiterated a “sector perform” rating and set a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday. Baird R W downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Finally, Cantor Fitzgerald raised Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 14th. Eight investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Intra-Cellular Therapies currently has a consensus rating of “Moderate Buy” and an average target price of $102.15.
View Our Latest Report on Intra-Cellular Therapies
Intra-Cellular Therapies Profile
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
See Also
- Five stocks we like better than Intra-Cellular Therapies
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- The How and Why of Investing in Gold Stocks
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- What is a Secondary Public Offering? What Investors Need to Know
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.